Meeting Banner
Abstract #0233

Semi-quantitative MRI Assessment of anti-PD1 Immunotherapy Response in Recurrent Glioblastoma

Lei Qin1,2, Xiang Li2,3, Amanda Stroiney4, David A Reardon1,2, and Geoffrey Young2,3

1Dana-Farber Cancer Institute, boston, MA, United States, 2Harvard Medical School, boston, MA, United States, 3Brigham and Women's Hospital, Boston, MA, United States, 4Northeastern University, Boston, MA, United States

The purpose of this study is to evaluate the predictive value of quantitative and semi-quantitative MRI biomarkers in determining patient benefit in anti-PD1 immunotherapy treatments. Longitudinal MRIs were performed on patients diagnosed with recurrent GBM. Volumetric analysis of abnormal tissue from contrast enhanced T1, FLAIR, and ADC revealed two distinct patterns: a) progressive increase volume in patients who derived no significant benefit, and b) a transient increase in the volume, followed by a delayed decrease in patients with >6 mo survival on trial. In this preliminary study (n=10), the data suggest that the volume of abnormal tissue on ADC seems to correlate better with patient benefit than abnormality on FLAIR and T1.

This abstract and the presentation materials are available to members only; a login is required.

Join Here